The content on this site is intended for healthcare professionals only
Dr Roy Herbst speaks to ecancer about updated long-term results from the phase III ADAURA trial.
The results further demonstrate the survival benefit of three years of adjuvant osimertinib in patients with resected EGFR-mutated stage IB-IIIA NSCLC.
In the overall population, the 8-year overall survival rate was 79% with osimertinib versus 64% with placebo, with a 48% reduction in the risk of death.
In patients with stage II-IIIA disease, the 8-year survival rate was 74% versus 58%.
Dr Herbst explores the durability of the survival benefit following completion of adjuvant treatment and outcomes across predefined patient subgroups.
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance
